Regulatory
Matters |
|
Bevacizumab
|
|
Calcium
gluconate injection |
|
Daptomycin |
|
Droperidol
Injection USP |
|
Risk
of severe arrhythmia |
|
Influenza
virus vaccine |
|
Label
change due to risk of fever and febrile seizure |
|
Lamotrigine |
|
Methylnaltrexone
bromide |
|
Midodrine
hydrochloride |
|
Modafinil |
|
Modified-release oral opioids |
|
Octagam
(intravenous immunoglobulin) |
|
Rosiglitazone |
|
Saquinavir |
|
Tigecycline |
|
Topical
ketoprofen |
Safety of Medicines |
|
Antidepressants |
|
Carbidopa/levodopa
and entacapone |
|
Dexrazoxane. |
|
Estradiol
transdermal spray |
|
H1N1
pandemic vaccines and antiviral |
|
Inhaled
and intranasal corticosteroids |
|
Isotretinoin |
|
Lithium. |
|
Monoclonal
antibodies |
|
Nimodipine
oral capsules |
|
Pioglitazone |
|
Propolis |
|
Tocilizumab
|
Feature |
|
Pharmacovigilance |
|
Meeting
of the Global Advisory Committee on Vaccine Safety |
|
Handling
of complaints of prequalified medicines |